US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma Corporation (MTPC) to enhance the development of Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS). This collaboration aims to address the mislocalization of the TAR DNA-binding protein 43 (TDP-43), a critical splicing factor involved in several neurodegenerative diseases and a key pathological feature present in over 97% of ALS patients.
Financial Terms and Development Objectives
Under the terms of the agreement, Dewpoint will receive an upfront payment and be eligible for milestone payments based on specified near-term research and development objectives. The total nominal deal value is up to USD 480 million. Upon achieving these milestones, MTPC will have an exclusive option to license the program and will assume responsibility for global clinical development and commercialization efforts.
Royalties and Commercialization
Dewpoint will also receive tiered royalties on net sales of the product, should MTPC exercise its option to license the program. This partnership underscores the potential impact of Dewpoint’s TDP-43 c-mod on the treatment landscape for ALS and other neurodegenerative diseases.-Fineline Info & Tech
Leave a Reply